FDA Considers Meeting With Firms Before Ordering Section 522 Studies

FDA’s device center seems agreeable to the concept of “pre-522” study meetings, raised by industry last week as a means to make the post-market study order process more efficient.

More from Regulation

More from Policy & Regulation